Suvorexant

舒沃雷生

Report date: 2026/02/19 20:00:18
NMEFirst In Class

Base Information

Drug NameSuvorexant
Drug Alias Name苏沃雷生SuvorexantumBelsomraMK-4305
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionOrexin receptor type 1 antagonistsOrexin receptor type 2 antagonists
TargetsOrexin receptor type 1Orexin receptor type 2
Therapy Area/IndicationsStress Disorders, Post-TraumaticAutistic DisorderAutism Spectrum Disorder +[18] 
Global Approved IndicationsSleep Initiation and Maintenance Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2014/08/13
Country/TerritoryUnited StatesNetherlandsAustralia +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineMerck Sharp & Dohme CorpThe University Of Texas Health Science Center At Houston +[12] 
Inactive CompaniesSleep Research Institute (Paseo De La Habana 151, Madrid 28036, Spain)The Florey Institute Of Neuroscience And Mental HealthWayne State University +[4] 
Active IndicationsStress Disorders, Post-TraumaticAutistic DisorderAutism Spectrum Disorder +[13] 
Inactive IndicationsAnxietyCocaine-Related DisordersRestless Legs Syndrome +[5] 

Other Information

ATC CodeN05CJ01
Related LinksWikipediaDrugBankKEGG